Liposomal irinotecan with cisplatin and radiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding liposomal irinotecan to standard chemotherapy and radiation for locally advanced esophageal squamous cell cancer. The goal is to see if this combination works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that has not spread to other parts of the body
- You are between 18 and 75 years old
- You have not had any prior treatment for your esophageal cancer
- You are generally in good health, able to take care of yourself, and have adequate organ function
- You do not have serious heart disease, lung disease, or active infections like hepatitis B or C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people whose esophageal cancer didn't respond to or couldn't tolerate the first treatment. The goal is to see if this second-line therapy can shrink tumors or slow their growth.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.